CAMBRIDGE, Mass., June 6 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) today announced the conclusion of its
collaboration with ICOS Corporation to develop LFA-1
(Leukocyte Function-associated Antigen-1) antagonists. IC747, an orally
administered LFA-1 antagonist, was designed to interfere with T-cell
activation and leukocyte trafficking by inhibiting the binding of LFA-1 to its
ligand. Biogen and ICOS were studying IC747 as a possible oral therapeutic
for the treatment of inflammatory conditions.
(Logo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
About Biogen
Biogen is the world's oldest independent biotechnology company and a
leader in biologics research, development and manufacturing. A pioneer in
leading edge research in immunology, neurobiology and oncology, Biogen brings
novel therapies to improve patients' lives around the world through its global
marketing capabilities. For press releases and additional information about
the company, please visit http://www.biogen.com.
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Media - Amy McKnight, Associate Director,
Public Affairs, +1-617-914-6524, or Investment - Christina
Dillon, Manager, Investor Relations, +1-617-679-2812, both of
Biogen, Inc.
|
